Preston Hupart, DO
Interventional Cardiology · Jersey City, NJNPI 1487610796
Payments from drug & device makers
Across 266 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$663
- Medtronic$649
- Novartis$583
- Amgen$428
- E.r. Squibb & Sons, L.L.C.$421
- Boehringer Ingelheim$367
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,54699%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 42 | $663 |
| Medtronic(2 entities) | 13 | $649 |
| Novartis | 38 | $583 |
| Amgen | 23 | $428 |
| E.r. Squibb & Sons, L.L.C. | 26 | $421 |
| Boehringer Ingelheim | 25 | $367 |
| Heartflow, Inc. | 6 | $351 |
| Boston Scientific | 6 | $323 |
| Pfizer | 20 | $308 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $174 |
| AstraZeneca | 11 | $153 |
| W. L. Gore & Associates, Inc. | 9 | $142 |
| Novo Nordisk | 2 | $127 |
| Edwards Lifesciences | 1 | $124 |
| Intra-sana Laboratories | 1 | $117 |
| Johnson & Johnson | 7 | $104 |
| Abbott | 3 | $74 |
| Atricure, Inc. | 1 | $63 |
| Amarin Pharma, Inc. | 4 | $57 |
| Inari Medical, Inc. | 2 | $56 |
| ZOLL Circulation Inc | 2 | $55 |
| Cardiva Medical, Inc. | 2 | $45 |
| Impulse Dynamics (USA) Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Cordis US CORP. | 1 | $28 |
| GSK | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$240
- CLARIA MRI QUAD CRT-D SURESCAN$160
- FFRangio$150
- FFRct$149
- Repatha$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$124
- Viva$124
- GLYCATE$117
- Reltone 400 Mg$117
- Reltone 200 Mg$117
How this compares
$5,590 in reported general payments places this provider in the 30th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $244,245 |
| XareltoRivaroxaban | 92 | $109,824 |
| EntrestoSacubitril/Valsartan | 95 | $107,069 |
| JardianceEmpagliflozin | 57 | $59,990 |
| Repatha SureclickEvolocumab | 35 | $30,003 |
| LivaloPitavastatin Calcium | 15 | $13,369 |
| FarxigaDapagliflozin Propanediol | 18 | $12,231 |
| Praluent PenAlirocumab | 16 | $12,208 |
| Metoprolol Succinate | 669 | $8,989 |
| BystolicNebivolol Hcl | 16 | $8,594 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $8,351 |
| VascepaIcosapent Ethyl | 12 | $8,321 |
| Pitavastatin Calcium | 25 | $7,040 |
| Rosuvastatin Calcium | 402 | $6,839 |
| Atorvastatin Calcium | 612 | $6,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $308 | $244,245218 claims |
| Johnson & JohnsonXarelto | $104 | $109,82492 claims |
| NovartisEntresto | $583 | $107,06995 claims |
| Boehringer IngelheimJardiance | $367 | $59,99057 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $40 | $21,96231 claims |
| AstraZenecaFarxiga | $153 | $12,23118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Jersey City
- Michael BenzJersey City$40K
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ramin HastingsHasbrouck Heights$355K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.